Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Inactivation of a class A and a class C β-lactamase by 6β-(hydroxymethyl)penicillanic acid sulfone.

Papp-Wallace KM, Bethel CR, Gootz TD, Shang W, Stroh J, Lau W, McLeod D, Price L, Marfat A, Distler A, Drawz SM, Chen H, Harry E, Nottingham M, Carey PR, Buynak JD, Bonomo RA.

Biochem Pharmacol. 2012 Feb 15;83(4):462-71. doi: 10.1016/j.bcp.2011.11.015. Epub 2011 Dec 2.

2.

Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.

Flanagan ME, Brickner SJ, Lall M, Casavant J, Deschenes L, Finegan SM, George DM, Granskog K, Hardink JR, Huband MD, Hoang T, Lamb L, Marra A, Mitton-Fry M, Mueller JP, Mullins LM, Noe MC, O'Donnell JP, Pattavina D, Penzien JB, Schuff BP, Sun J, Whipple DA, Young J, Gootz TD.

ACS Med Chem Lett. 2011 Mar 2;2(5):385-90. doi: 10.1021/ml200012f. eCollection 2011 May 12.

3.

Antimicrobial Chemotherapy.

Neu HC, Gootz TD.

In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 11.

4.

The global problem of antibiotic resistance.

Gootz TD.

Crit Rev Immunol. 2010;30(1):79-93. Review.

PMID:
20370622
5.

Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.

Gootz TD, Lescoe MK, Dib-Hajj F, Dougherty BA, He W, Della-Latta P, Huard RC.

Antimicrob Agents Chemother. 2009 May;53(5):1998-2004. doi: 10.1128/AAC.01355-08. Epub 2009 Mar 2.

6.

Acinetobacter baumannii: an emerging multidrug-resistant threat.

Gootz TD, Marra A.

Expert Rev Anti Infect Ther. 2008 Jun;6(3):309-25. doi: 10.1586/14787210.6.3.309. Review.

PMID:
18588496
7.

Bacterial efflux pump inhibitors.

Kamicker BJ, Sweeney MT, Kaczmarek F, Dib-Hajj F, Shang W, Crimin K, Duignan J, Gootz TD.

Methods Mol Med. 2008;142:187-204. doi: 10.1007/978-1-59745-246-5_15.

PMID:
18437315
8.

Enterococcal virulence determinants may be involved in resistance to clinical therapy.

Marra A, Dib-Hajj F, Lamb L, Kaczmarek F, Shang W, Beckius G, Milici AJ, Medina I, Gootz TD.

Diagn Microbiol Infect Dis. 2007 May;58(1):59-65. Epub 2007 Feb 14.

PMID:
17300898
10.

The forgotten Gram-negative bacilli: what genetic determinants are telling us about the spread of antibiotic resistance.

Gootz TD.

Biochem Pharmacol. 2006 Mar 30;71(7):1073-84. Epub 2005 Dec 13. Review.

PMID:
16359640
11.

Minimum inhibitory concentrations of tulathromycin against respiratory bacterial pathogens isolated from clinical cases in European cattle and swine and variability arising from changes in in vitro methodology.

Godinho KS, Keane SG, Nanjiani IA, Benchaoui HA, Sunderland SJ, Jones MA, Weatherley AJ, Gootz TD, Rowan TG.

Vet Ther. 2005 Summer;6(2):113-21.

PMID:
16094559
12.

Global dissemination of beta-lactamases mediating resistance to cephalosporins and carbapenems.

Gootz TD.

Expert Rev Anti Infect Ther. 2004 Apr;2(2):317-27. Review.

PMID:
15482196
13.

The current state of antibacterial research.

Gootz TD.

Expert Rev Anti Infect Ther. 2003 Jun;1(1):1-3. No abstract available.

PMID:
15482097
14.

Genetic and molecular characterization of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae with unusually high resistance to ampicillin.

Kaczmarek FS, Gootz TD, Dib-Hajj F, Shang W, Hallowell S, Cronan M.

Antimicrob Agents Chemother. 2004 May;48(5):1630-9.

15.

Cloning and functional characterization of an NAD(+)-dependent DNA ligase from Staphylococcus aureus.

Kaczmarek FS, Zaniewski RP, Gootz TD, Danley DE, Mansour MN, Griffor M, Kamath AV, Cronan M, Mueller J, Sun D, Martin PK, Benton B, McDowell L, Biek D, Schmid MB.

J Bacteriol. 2001 May;183(10):3016-24.

16.

Bactericidal assays for fluoroquinolones.

Gootz TD.

Methods Mol Biol. 2001;95:185-94. No abstract available.

PMID:
11089231
17.

Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.

Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N.

Biochemistry. 2000 Mar 14;39(10):2726-32.

PMID:
10704224
18.

Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.

Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N.

J Biol Chem. 1999 Dec 10;274(50):35927-32.

19.

Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.

Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE.

Antimicrob Agents Chemother. 1999 Aug;43(8):1845-55.

20.

Anti-Toxoplasma gondii activities and structure-activity relationships of novel fluoroquinolones related to trovafloxacin.

Khan AA, Araujo FG, Brighty KE, Gootz TD, Remington JS.

Antimicrob Agents Chemother. 1999 Jul;43(7):1783-7.

21.

Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.

Pechère JC, Gootz TD.

Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):405-12. Review.

PMID:
9758283
22.

Topoisomerase IV catalysis and the mechanism of quinolone action.

Anderson VE, Gootz TD, Osheroff N.

J Biol Chem. 1998 Jul 10;273(28):17879-85.

23.

New quinolone compounds from Pseudonocardia sp. with selective and potent anti-Helicobacter pylori activity: taxonomy of producing strain, fermentation, isolation, structural elucidation and biological activities.

Dekker KA, Inagaki T, Gootz TD, Huang LH, Kojima Y, Kohlbrenner WE, Matsunaga Y, McGuirk PR, Nomura E, Sakakibara T, Sakemi S, Suzuki Y, Yamauchi Y, Kojima N.

J Antibiot (Tokyo). 1998 Feb;51(2):145-52.

24.

CJ-12,954 and its congeners, new anti-Helicobacter pylori compounds produced by Phanerochaete velutina: fermentation, isolation, structural elucidation and biological activities.

Dekker KA, Inagaki T, Gootz TD, Kaneda K, Nomura E, Sakakibara T, Sakemi S, Sugie Y, Yamauchi Y, Yoshikawa N, Kojima N.

J Antibiot (Tokyo). 1997 Oct;50(10):833-9.

25.

In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae.

Klugman KP, Gootz TD.

J Antimicrob Chemother. 1997 Jun;39 Suppl B:51-5.

PMID:
9222070
26.

The chemistry and biological profile of trovafloxacin.

Brighty KE, Gootz TD.

J Antimicrob Chemother. 1997 Jun;39 Suppl B:1-14. Review.

PMID:
9222064
27.

Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.

Gootz TD, Zaniewski R, Haskell S, Schmieder B, Tankovic J, Girard D, Courvalin P, Polzer RJ.

Antimicrob Agents Chemother. 1996 Dec;40(12):2691-7.

28.

Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects.

Gootz TD, Brighty KE.

Med Res Rev. 1996 Sep;16(5):433-86. Review. No abstract available.

PMID:
8865150
29.

Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys.

Teng R, Girard D, Gootz TD, Foulds G, Liston TE.

Antimicrob Agents Chemother. 1996 Mar;40(3):561-6.

30.
31.
32.

In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.

Gootz TD, Brighty KE, Anderson MR, Schmieder BJ, Haskell SL, Sutcliffe JA, Castaldi MJ, McGuirk PR.

Diagn Microbiol Infect Dis. 1994 Aug;19(4):235-43.

PMID:
7851087
33.

Bisulfite or sulfite inhibits growth of Helicobacter pylori.

Hawrylik SJ, Wasilko DJ, Haskell SL, Gootz TD, Lee SE.

J Clin Microbiol. 1994 Mar;32(3):790-2.

34.

Immunological and molecular characterization of Helicobacter felis urease.

Gootz TD, Perez-Perez GI, Clancy J, Martin BA, Tait-Kamradt A, Blaser MJ.

Infect Immun. 1994 Mar;62(3):793-8.

35.
37.

Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme.

Froelich-Ammon SJ, McGuirk PR, Gootz TD, Jefson MR, Osheroff N.

Antimicrob Agents Chemother. 1993 Apr;37(4):646-51.

38.

Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals.

Girard D, Gootz TD, McGuirk PR.

Antimicrob Agents Chemother. 1992 Aug;36(8):1671-6.

39.

Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group.

Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Osheroff N.

Antimicrob Agents Chemother. 1992 Apr;36(4):751-6.

40.

High-level quinolone resistance in clinical isolates of Campylobacter jejuni.

Segreti J, Gootz TD, Goodman LJ, Parkhurst GW, Quinn JP, Martin BA, Trenholme GM.

J Infect Dis. 1992 Apr;165(4):667-70.

PMID:
1313069
41.

Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.

McGuirk PR, Jefson MR, Mann DD, Elliott NC, Chang P, Cisek EP, Cornell CP, Gootz TD, Haskell SL, Hindahl MS, et al.

J Med Chem. 1992 Feb 21;35(4):611-20.

PMID:
1311762
42.

Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.

Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Moynihan M, Sutcliffe JA, Osheroff N.

J Biol Chem. 1991 Aug 5;266(22):14585-92.

43.

Characterization of high-level quinolone resistance in Campylobacter jejuni.

Gootz TD, Martin BA.

Antimicrob Agents Chemother. 1991 May;35(5):840-5.

44.

Discovery and development of new antimicrobial agents.

Gootz TD.

Clin Microbiol Rev. 1990 Jan;3(1):13-31. Review.

45.

Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems.

Gootz TD, Barrett JF, Sutcliffe JA.

Antimicrob Agents Chemother. 1990 Jan;34(1):8-12. Review. No abstract available.

46.

In vitro assays used to measure the activity of topoisomerases.

Barrett JF, Sutcliffe JA, Gootz TD.

Antimicrob Agents Chemother. 1990 Jan;34(1):1-7. Review. No abstract available.

47.

Biochemical characteristics and physiological significance of major DNA topoisomerases.

Sutcliffe JA, Gootz TD, Barrett JF.

Antimicrob Agents Chemother. 1989 Dec;33(12):2027-33. Review. No abstract available.

48.

Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents.

Barrett JF, Gootz TD, McGuirk PR, Farrell CA, Sokolowski SA.

Antimicrob Agents Chemother. 1989 Oct;33(10):1697-703.

49.

Simple spectrophotometric assay for measuring protein binding of penem antibiotics to human serum.

Gootz TD, Subashi TA, Lindner DL.

Antimicrob Agents Chemother. 1988 Feb;32(2):159-63.

50.

Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.

Girard AE, Girard D, English AR, Gootz TD, Cimochowski CR, Faiella JA, Haskell SL, Retsema JA.

Antimicrob Agents Chemother. 1987 Dec;31(12):1948-54.

Supplemental Content

Loading ...
Support Center